RT Journal Article
T1 Serum autoantibody biomarkers for management of rheumatoid arthritis disease
A1 Sánchez Tirado, Esther
A1 Agüí Chicharro, María Lourdes
A1 Sánchez-Paniagua López, Marta
A1 González Cortés, Araceli
A1 López Ruiz, María Beatriz
A1 Yáñez-Sedeño Orive, Paloma
A1 Pingarrón Carrazón, José Manuel
AB Rheumatoid arthritis (RA) is a systemic chronic autoimmune inflammatory disease that is characterized by the destruction of bone and production of autoantibodies such as rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPAs). The high prevalence of this disease and the need of affordable tools for its early detection led us to prepare the first electrochemical immunoplatform for the simultaneous determination of four RA biomarkers, the autoantibodies: RF, anti-peptidyl-arginine deiminase enzyme (anti-PAD4), anti-cyclic citrullinated peptide (anti-CCP), and anti-citrullinated vimentin (anti-MCV). Functionalized magnetic beads (MBs) were used to immobilize the specific antigens, and sandwich-type immunoassays were implemented for the amperometric detection of the four autoantibodies, using the horseradish peroxidase (HRP)/H2O2/hydroquinone (HQ) system. The immunoplatform was applied to the determination of the biomarkers in human serum of twenty-two patients diagnosed with RA and four healthy individuals, and the results were validated against ELISA tests and the certified values.
PB MDPI
SN 2079-6374
YR 2023
FD 2023
LK https://hdl.handle.net/20.500.14352/92755
UL https://hdl.handle.net/20.500.14352/92755
LA eng
NO Sánchez-Tirado E, Agüí L, Sánchez-Paniagua M, González-Cortés A, López-Ruiz B, Yáñez-Sedeño P, et al. Serum autoantibody biomarkers for management of rheumatoid arthritis disease. Biosensors (Basel). 2023 Mar 13; 13(3): 381-94
NO Ministerio de Ciencia e Innovación (España)
NO Comunidad de Madrid
DS Docta Complutense
RD 20 abr 2025